Ghassan Abou-Alfa, MD
Memorial Sloan Kettering Cancer Center
6
6
4
N/A
0
13
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Eric K Rowinsky, MD
Uniphar Development, LLC
Shared therapeutic areas:
Worked with same sponsors:
Gary K. Schwartz, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Robert L. DeJager, MD, FACP
Daiichi Sankyo
Shared therapeutic areas:
howard Safran, MD
Brown University
Shared therapeutic areas:
Worked with same sponsors:
Steven R. Alberts, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Heinz-Josef Lenz, MD
University of Southern California
Shared therapeutic areas:
Worked with same sponsors:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Eric Bellissant, MD, PhD
Rennes University Hospital
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
All 6 trials loaded